Viage
San Francisco Bay Area, US · Founded 2018 · 4 known investors
Find your way into Viage
Sign up to see every warm intro you have to Viage
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Viage team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.
Founders & leadership
Viage was founded in 2018 by Kousaku Ohinata, Ph.D..
KO
Kousaku Ohinata, Ph.D.Founder, Scientific Advisor
NS
Investors · 4
Frequently asked questions
- What does Viage do?
- Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.
- Who founded Viage?
- Viage was founded by Kousaku Ohinata, Ph.D. in 2018.
- Who are Viage's investors?
- Viage's investors include Kyoto University Innovation Capital, Miyako Capital, RDiscovery, Remiges Ventures, Inc..
- Where is Viage headquartered?
- Viage is headquartered in San Francisco Bay Area, US.
